Marico Gets Extension to Complete Acquisition of Remaining 40% in Satia Nutraceuticals

FMCG major Marico Ltd informed exchanges that it has received approval to extend the timeline for purchasing the outstanding 40% equity stake in Satia Nutraceuticals Pvt Ltd. This follows Marico's earlier acquisition of a majority stake, positioning the company to fully integrate its nutraceuticals operations.

The extension accommodates regulatory clearances, valuation finalization, and transaction structuring, common in cross-border or complex JV buyouts. Satia Nutraceuticals specializes in premium health supplements, aligning with Marico's expansion into high-margin wellness categories like immunity boosters and personal nutrition products.

Full ownership will streamline decision-making and accelerate product launches.

Key Highlights:

Transaction: Extension to buy remaining 40% stake in Satia Nutraceuticals.

Strategic Asset: Health supplements and nutraceuticals JV.

Rationale: Regulatory/valuation timelines extended.

Business Fit: Bolsters Marico's wellness and premium FMCG portfolio.

Outcome: Enables 100% ownership for operational synergy.

Source: Company filing to BSE/NSE, December 17, 2025.